Analysts Expect Pieris Pharmaceuticals Inc. (PIRS) to Post ($0.13) Earnings Per Share
Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price target of $8.00 for the company and are predicting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also given Pieris Pharmaceuticals an industry rank of 105 out of 265 based on the ratings given to its competitors.
A number of analysts recently issued reports on the company. Roth Capital reissued a “buy” rating and set a $6.00 price objective on shares of Pieris Pharmaceuticals in a research report on Wednesday, September 28th. Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $10.00 price objective on shares of Pieris Pharmaceuticals in a research report on Wednesday, September 28th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/analysts-expect-pieris-pharmaceuticals-inc-pirs-to-post-0-13-earnings-per-share.html
A number of institutional investors have recently made changes to their positions in PIRS. BlackRock Fund Advisors purchased a new position in shares of Pieris Pharmaceuticals during the second quarter worth approximately $113,000. Frontier Wealth Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the second quarter worth approximately $137,000. Sabby Management LLC boosted its position in shares of Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company’s stock worth $333,000 after buying an additional 99,792 shares during the period. BVF Inc. IL purchased a new position in shares of Pieris Pharmaceuticals during the second quarter worth approximately $389,000. Finally, Lombard Odier Asset Management USA Corp boosted its position in shares of Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the period. Institutional investors own 45.79% of the company’s stock.
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) traded up 1.26% on Wednesday, reaching $1.61. The company had a trading volume of 27,040 shares. Pieris Pharmaceuticals has a 52-week low of $1.26 and a 52-week high of $3.08. The firm’s market capitalization is $69.32 million. The company has a 50-day moving average price of $1.67 and a 200-day moving average price of $1.78.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Wednesday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative return on equity of 52.21% and a negative net margin of 346.01%. The business earned $1.07 million during the quarter. Equities research analysts forecast that Pieris Pharmaceuticals will post ($0.55) EPS for the current fiscal year.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.